Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
administered, arm, broader, castration, CI, Cologne, conference, daily, detect, dose, essential, feedback, Germany, hazard, HR, individual, lt, median, mg, notably, permission, pertaining, PFS, placebo, ratio, Reinvestment, remit, renamed, shareholder, size, SPA, spent, subsidiary, Taconic, threshold, treasury, upcoming, writing
Removed:
calculation, owe, study
Filing tables
Filing exhibits
- 10-Q Quarterly report
- 10.1 Separation Agreement and Release - Frances. K. Heller
- 10.2 Change In Control and Severance Benefit Plan, As Amended and Restated.
- 10.3 Sublease Between Exelixis, Inc. and Nodality, Inc.
- 10.4 Consent to Sublease by HCP Life Sciences, Exelixis and Nodality, Inc.
- 10.5 Sublease Between Exelixis, Inc. and Threshold Pharmaceuticals, Inc.
- 10.6 Consent to Sublease by HCP Life Sciences, Exelixis and Threshold Pharmaceuticals
- 10.7 Amendment No. 11 to the Loan and Security Agreement
- 10.8 Severance/consulting Agreement and Release - Lupe M. Rivera
- 31.1 Certification Required by Rule 13A-14(A) or Rule 15D-14(A).
- 31.2 Certification Required by Rule 13A-14(A) or Rule 15D-14(A).
- 32.1 Certification by the CEO & CFO Required by 13A-14(B) or 15D-14(B) & Section 1350
Related press release
EXEL similar filings
Filing view
External links